EUVIMEDEUVIMED entdecken
Editorial

Lirafugratinib (Lyrfigtu®): a first-in-class, highly selective FGFR2 inhibitor approved for advanced cholangiocarcinoma

Miao Liu, Xingyue Ji iD

Medicinal Chemistry Research · 14.11.2026

DOI: 10.1007/s00044-026-03641-3 ↗

Kurz gefasst

Editorial in der Zeitschrift Medicinal Chemistry Research, online erschienen am 14.11.2026. Verfasst von Miao Liu und 1 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Science, Soochow University, Suzhou, 215021, Jiangsu, China. Die Arbeit nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements are validated oncogenic drivers in intrahepatic cholangiocarcinoma. The US FDA recently approved the highly selective inhibitor lirafugratinib (Lyrfigtu^®) for adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement. First-generation pan-FGFR inhibitors are limited by FGFR1-mediated hyperphosphatemia and rapid acquired resistance, highlighting the need for FGFR2-selective inhibitors. Guided by long-timescale molecular dynamics simulations, researchers identified differential dynamics in the kinase P-loop between FGFR1 and FGFR2. Lirafugratinib was rationally engineered to covalently engage Cys491 in FGFR2, while stabilizing the FGFR1 P-loop in a conformation that locks its corresponding cysteine out of reactive reach. This structural ingenuity confers > 250-fold selectivity over FGFR1, thus mitigating phosphate toxicity and effectively bypassing steric clashes caused by clinical gatekeeper mutations (e.g., V564F). In the pivotal ReFocus trial, lirafugratinib demonstrated robust, durable clinical efficacy alongside a highly manageable safety profile, and was thus approved without undergoing phase 3 clinical trials. Lirafugratinib (Lyrfigtu) is shown for FGFR2-altered cholangiocarcinoma. It bypasses steric clash and exploits a dynamic pocket. Listed properties include more than 250-fold selectivity over FGFR1, reduced hyperphosphatemia, and overcoming the V564F mutation.

Schlagwörter

Stichwörter der Autor:innen

CholangiocarcinomaFGFR2Gatekeeper mutationLirafugratinibMolecular dynamics

Autor:innen und Institutionen

  • College of Pharmaceutical Science, Soochow University, Suzhou, 215021, Jiangsu, China.
  • College of Pharmaceutical Science, Soochow University, Suzhou, 215021, Jiangsu, China. jixy@suda.edu.cn.

ORCID-Profile: Xingyue Ji

Zitieren

APA

Liu, M., & Ji, X. (2026). Lirafugratinib (Lyrfigtu®): a first-in-class, highly selective FGFR2 inhibitor approved for advanced cholangiocarcinoma. Medicinal Chemistry Research. https://doi.org/10.1007/s00044-026-03641-3

Vancouver

Liu M, Ji X. Lirafugratinib (Lyrfigtu®): a first-in-class, highly selective FGFR2 inhibitor approved for advanced cholangiocarcinoma. Medicinal Chemistry Research. 2026. doi:10.1007/s00044-026-03641-3

BibTeX
@article{Liu2026,
  author = {Liu, Miao and Ji, Xingyue},
  title = {Lirafugratinib (Lyrfigtu®): a first-in-class, highly selective FGFR2 inhibitor approved for advanced cholangiocarcinoma},
  journal = {Medicinal Chemistry Research},
  year = {2026},
  doi = {10.1007/s00044-026-03641-3}
}
Kostenlos starten →